Compare Incyte Corporation (INCY) vs NVR Inc. Common Stock (NVR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs NVR Inc. Common Stock — how do they compare? Incyte Corporation trades at $111.6 (market cap $22.63B), while NVR Inc. Common Stock trades at $5,845.81 (market cap $15.28B). The key difference: Incyte Corporation is the larger of the two by market cap, and NVR Inc. Common Stock is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and NVR Inc. Common Stock for 0 Days on average.
| INCY | NVR | |
|---|---|---|
Market Cap | $22.63B | $15.28B |
Volume | 1,869,988 | 53,948 |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $8.10K |
52-Week Low | $86.17 | $5.56K |
Typical Hold Time | 33 Days | 0 Days |
Enterprise Value | $18.13B | $15.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $108.62, down 2.46% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 13.84, robust profitability margins, and a significant earnings beat in Q2 2026. Recent news highlights FDA approval for Atebrioz and a strategic push for post-JAKAFI growth targeting $4B in sales. Operating cash flow surged to $1.41B in 2025, supporting financial health.
The outlook is mixed: analyst consensus is bullish with a $133.14 price target, but near-term technical pressure and Q3 2026's expected EPS loss pose risks. Long-term growth depends on pipeline execution and diversification beyond JAKAFI, with competitive and regulatory challenges as key investor considerations.
NVR trades at $5,797.61, up 0.83% today, with a P/E of 15.07 and P/S of 1.79. Recent earnings missed estimates in Q1 and Q2 2026, with revenue and net income projected to decline in 2026. The stock faces headwinds from margin pressure and softer homebuyer demand, as highlighted by Zacks naming it Bear of the Day on October 9, 2026. Despite this, strong profitability metrics like a 31.54% ROE and consistent cash flow from operations support its financial resilience.
The outlook is cautious due to earnings misses and a projected revenue drop, but the asset-light model and share buybacks provide stability. Risks include mortgage rate sensitivity and competitive pressures, while analyst consensus leans neutral with a $6,550 price target. Patient investors may find value if housing demand recovers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About NVR Inc. Common Stock
NVR Inc. is a homebuilder operating through homebuilding and mortgage banking segments, building single-family homes, townhomes, and condominiums under the Ryan Homes, NVHomes, and Heartland Homes brands. It uses a land-light model, acquiring lots through third-party option agreements rather than holding large land inventories, and provides mortgage and title services through NVR Mortgage.
Read more on NVR →
